iBET is very pleased to announce that Dr. Hitto Kaufmann has been appointed as a new member of the Scientific Advisory Board (SAB) of iBET.
Dr. Kaufmann is currently Senior Vice President and Chief Scientific Officer of Pieris Pharmaceuticals and Vice Chairman of the European Society of Animal Cell Technology. Dr. Kaufmann has over 20 years of experience in research, development and manufacturing of therapeutic biological entities. Prior to joining Pieris, Dr. Kaufmann held several executive positions at Sanofi and Boehringer Ingelheim. Dr. Kaufmann obtained his Ph.D. in Natural Science, at the Swiss Federal Institute of Technology in Zurich and a Master of Science degree in Biotechnology from the Technical University of Braunschweig and The Scripps Research Institute.
“We are delighted to welcome Dr. Hitto Kaufmann to iBET’s Scientific Advisory Board” said Dr Paula Alves, CEO of iBET, “Dr. Kaufmann has a distinguished track record within the biotech and pharmaceutical industry and will add considerable value to iBET. His knowledge and expertise will be an invaluable resource as we continue to invest in strengthening our partnerships with the life sciences industry”.
“I am joining the Scientific Advisory Board of iBET at tremendously exciting times” said Dr. Kaufmann. “Next generation biologics and the emergence of advanced therapy medicinal products demand new and improved bioprocesses and R&D technology platforms. iBET’s competences in these fields are impressive thus, as a member of iBET’s SAB, I am looking forward to closely follow iBET’s development and to contribute to leveraging iBET’s competences in global networks with their distinguished partners”.